Brought to you by 
Abeona licenses REGENXBIO's NAV AAV9 vector for rare lysosomal storage diseases; Agreement Terminated/Cancelled
04 Dec 2020
Executive Summary
Abeona Therapeutics Inc. licensed REGENXBIO Inc.'s adeno-associated virus vector NAV AAV9 to develop and commercialize in vivo gene therapies for four rare inherited lysosomal storage disorders (LSDs): Sanfilippo syndrome Type A (or mucopolysaccharidosis (MPS) IIIA), Sanfilippo syndrome Type B (MPS IIIB), neuronal ceroid lipofuscinosis Type 1 (CLN1, also known as infantile Batten disease), and CLN3 (also known as juvenile Batten disease).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abeona licenses REGENXBIO's NAV AAV9 vector for rare lysosomal storage diseases; Agreement Terminated/Cancelled
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice